Three drugs target resistant breast cancers driven by HER2 mutations
UT Southwestern Medical CenterA targeted therapy using three different drugs significantly delayed progression and extended survival for breast cancer patients whose HER2 gene is mutated, a multicenter study co-led by researchers at UT Southwestern Medical Center shows. The findings, published in Annals of Oncology, suggest a new strategy for a difficult-to-treat form of breast cancer that has become resistant to other treatments and currently has no curative options.